We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non-Invasive Imaging Detects Cancer at Molecular Level

By LabMedica International staff writers
Posted on 20 Aug 2019
For cancer patients the presence of metastases dictates the staging assessment, which in turn defines the appropriate treatment path selected. More...
For gynecological malignancies, like ovarian carcinoma, it is of immense importance to differentiate between localized and metastatic disease status as that drastically affects management.

For in situ, real time diagnosis, novel imaging modalities that offer metabolic and structural information at the cellular and subcellular level can be of great help, especially since these modalities are being progressively incorporated in probes and micro-endoscopes that allow intra-vital access to organs that lie deeper in the body.

Biomedical scientists at Tufts University (Medford, MA, USA) and their colleagues collected samples from eight patients who underwent open laparotomy as part of routine medical care. Post completion of all intra-abdominal procedures of the operation, eight biopsies of healthy parietal peritoneum and if present of four peritoneal metastases were collected from each patient. All lesions were evaluated by a pathologist using standard hematoxylin and eosin histology.

The tissues were imaged employing a multiphoton laser scanning microscope to generate intrinsic fluorescence and second harmonic generation (SHG) images at 755 nm and 900 nm excitation respectively with signal emission collected at 460 ± 20 and 525 ± 25 nm. Laser light was focused on the sample using a 25x objective (0.9 NA / water-immersion), and neutral density filters were employed to achieve a power of 25–35 mW. At least two to three random fields per tissue were evaluated, reaching a total of 30 and 11 images for the healthy and metastatic biopsy tissue groups, respectively (512 × 512 pixels; 600-micron field of view; resolution of 1.17 microns per pixel). Imaging was focused within a depth of ∼20-100 microns from the mesothelial surface of the tissues.

The team found that healthy tissues displayed large variations in contrast and correlation features as a function of distance, corresponding to repetitive, increased local intensity fluctuations. Metastatic tissue images exhibited decreased contrast and correlation related values, representing more uniform intensity patterns and smaller fibers, indicating the destruction of the healthy stroma by the cancerous infiltration. Analyzing 41 images acquired from the biopsies, the technique correctly classified 40 out of 41 images (an accuracy of 97.5%). A total of 11 samples were correctly classified as metastatic (100% sensitivity) and 29 of 30 were correctly classified as healthy (96.6% specificity).

Dimitra Pouli, MD, PhD, a Pathology Resident and co-author of the study, said, “The method utilized in this work identifies in a completely label-free manner cellular and tissue features at the microscopic level, essentially acting like a biopsy without a knife,” The study was published in the August 2019 issue of the journal Biomedical Optics Express.

Related Links:
Tufts University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.